MaxCyte, Inc. Total Voting Rights and Block Listing Return (5553I)
August 07 2023 - 12:01PM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 5553I
MaxCyte, Inc.
07 August 2023
MaxCyte, Inc.
("MaxCyte" or the "Company")
Total Voting Rights and Block Listing Return
ROCKVILLE, Md., August 07, 2023 -- MaxCyte (LSE: MXCT), a
leading commercial cell - engineering company focused on providing
enabling platform technologies to advance innovative cell-based
research as well as next-generation cell therapeutic discovery,
development and commercialization, announces that as of 31 July
2023, the total issued stock capital of the Company was 103,504,571
shares of common stock, $0.01 par ("Common Stock") following
further issue of new Common Stock in satisfaction of the exercise
of share options. Shareholders in the Company may use this figure
as the denominator for the calculations by which they will
determine if they are required to notify their interest in, or a
change to their interest in, the stock capital of the Company.
Block Listing Return
MaxCyte also makes the following notification pursuant to AIM
Rule 29 and Schedule Six of the AIM Rules for Companies, regarding
its existing block listings:
Name of applicant: MaxCyte, Inc.
Name of scheme: MaxCyte Long Term Incentive
Plan
----------------------------------
Period of return: From: 1 October To: 31 July 2023
2022
---------- ------------ ---- --------------
Balance of unallotted securities 11,529,603 ordinary shares of
under scheme(s) from previous common stock at $ 0.01 each
return:
----------------------------------
Plus: The amount by which the Nil
block scheme(s) has been increased
since the date of the last return
(if any increase has been applied
for):
----------------------------------
Less: Number of securities issued/allotted 1,600,258 ordinary shares of
under scheme(s) during period common stock at $ 0.01 each
(see LR3.5.7G):
----------------------------------
Equals: Balance under scheme(s) 9,929,345 ordinary shares of
not yet issued/allotted at end common stock at $ 0.01 each
of period:
----------------------------------
Name of contact: Douglas Swirsky, Chief Financial
Officer
Telephone number of contact: +1 301 944 1700
---------------------------------
For further information, please contact:
MaxCyte Contacts:
US IR Adviser +1 415-937-5400
Gilmartin Group ir@maxcyte.com
David Deuchler, CFA
Nominated Adviser and Joint Corporate Broker
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden +44 (0)20 7886 2500
UK IR Adviser +44 (0)203 709 5700
Consilium Strategic Communications maxcyte@consilium-comms.com
Mary-Jane Elliott
Chris Welsh
About MaxCyte
MaxCyte is a leading commercial cell-engineering company focused
on providing enabling platform technologies to advance innovative
cell-based research as well as next-generation cell therapeutic
discovery, development and commercialization. Over the past 20
years, we have developed and commercialized our proprietary Flow
Electroporation(R) platform, which facilitates complex engineering
of a wide variety of cells. Our ExPERT(TM) platform, which is based
on our Flow Electroporation technology, has been designed to
support the rapidly expanding cell therapy market and can be
utilized across the continuum of the high-growth cell therapy
sector, from discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: four instruments, the ATx(TM), STx(TM) GTx(TM)
and VLx(TM); a portfolio of proprietary related processing
assemblies or disposables; and software protocols, all supported by
a robust worldwide intellectual property portfolio.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVRDZGGRKNRGFZM
(END) Dow Jones Newswires
August 07, 2023 12:01 ET (16:01 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024